Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications. WEXFORD, Pa., Feb. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that ...

Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death WEXFORD, Pa., Feb. 7, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, today announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion ...

Table of Contents As filed with the Securities and Exchange Commission on November 14, 2023 Registration No. ___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) 105 Bradford Road, Suite 420 Wexford, Pennsylvania 15090 724-934-6467 (Address, including zip code and telephone number, including area code, of registrant's princ ...

Warrant Holder 13 – On January 28, 2022, Coeptis Therapeutics, Inc., issued a warrant to a third party in exchange for professional services, granting the warrant holder the right to purchase 225,000 shares of common stock at a price of $1.50 per share. The warrants expire on January 31, 2024. As part of the call, 15,000 warrants at $1.50 per share were exercised on March 1, 2022, and 210,000 warrants at $1.50 per share were exercised on September 14, 2022. As of September 30, 2023, there are no warrants ou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39669 Delaware 98-1465952 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: Securities registered pursuant to Sec ...

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Table of Contents As filed with the Securities and Exchange Commission on June 12, 2023 (State or other jurisdiction of incorporation) Registration No. 333-269782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-effective Amendment No. 4 to FORM S-1/A (Address, including zip code and telephone number, including area code, of registrant' ...

As filed with the Securities and Exchange Commission on June 6, 2023 Registration No. 333-269782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-ef ective Amendment No. 3 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) 105 Bradford Road, Suite 420 Wexford, Pennsylvania 15090 724-934-6467 (Address, including zip code and telephone number, including area code, of registr ...

Table of Contents As filed with the Securities and Exchange Commission on May 31, 2023 Registration No. 333-269782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-effective Amendment No. 2 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Primary Standard Industrial Classification Code Number) Delaware 2834 98-1465952 (I.R. ...

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from _____________ to _____________ Table of Contents x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 COEPW Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 COEPTIS THERAPEUTICS HOLDINGS, INC. Delaware 98-1465952 (State or other jurisdiction of incorporation or org ...

Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No. 333-269782 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-effective Amendment No. 1 to FORM S-1/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Primary Standard Industrial Classification Code Number) Delaware 2834 98-1465952 (I. ...